USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/28634
Title: Etiology, pathogenesis, diagnosis and treatment of ovarian cancer
Authors: Cheacir Anastasia
Issue Date: 2024
Publisher: Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova
Citation: Cheacir Anastasia. Etiology, pathogenesis, diagnosis and treatment of ovarian cancer. In: Abstract Book. MedEspera 2024. The 10th International Medical Congress for Students and Young Doctors. 24-27 April 2024, Chișinău, Republic of Moldova, p. 218. ISBN 978-9975-3544-2-4.
Abstract: Introduction. The 5th most common cause of death among women is caused by ovarian cancer. According to the American Cancer Society, the risk of being diagnosed with ovarian cancer throughout life for women is 1 in 78. In the US, it is expected to be detected in 2023, 19,710 new cases of ovarian cancer and about 13,270 deaths from ovarian cancer. Aim of study. To study and analyze the current articles on etiology, pathogenesis, diagnosis and treatment of ovarian cancer. Methods and materials. This abstract was done by exploring and analyzing medical publications from PubMed, Medscape, NCBI, MEDLINE. Results. Ovarian cancer is detected at an early stage only in 20-25%. Most often it is diagnosed in postmenopausal women. The primary risk factor is a family history of ovarian or breast cancer. First-line investigations include detection of CA-125 marker in blood and transvaginal ultrasonography. In addition, abdominal and pelvic CT, PET scanning and MRI of the pelvic region can be used to visualize the extension of the tumor. Currently, ovarian cancer treatment consists of combining surgery with chemotherapy. According to the latest data, laparoscopic surgery is preferred, as it is less invasive and has a faster recovery than debulking operations. Tumor progression and tumor recurrence occurs more frequently in advanced stages. Conclusion. Currently, ovarian cancer remains one of the most common causes of lethality in women, the main cause being the lack of effective strategies for early detection of ovarian cancer. The latest studies show that median survival for stage 1 ovarian cancer is between 70% and 90%, and for stage 4 it is less than 6%. According to the American Cancer Society, the risk of be ing diagnosed with ovarian cancer throughout life for women is 1 in 78. In the US, it is expect ed to be detected in 2023, 19,710 new cases of ovarian cancer and about 13,270 deaths from ovari an cancer. Aim of study. To study and analyze the current articles on etiology, pathogenesis, diagnosis and treatment of ovarian cancer. Methods and materials. This abstract was done by exploring and analyzing medical publications from PubMed, Medscape, NCBI, MEDLINE. Results. Ovarian cancer is detected at an early stage only in 20-25% . Most often it is diagnosed in postmenopausal women. The primary risk factor is a family hi story of ovarian or breast cancer. First-line investigations include detection of CA-125 marker in blood and transvaginal ultrasonography. In addition, abdominal and pelvic CT, PET scanning and MRI of the pelvic region can be used to visualize the extension of the tumor . Currently, ovarian cancer treatment consists of combining surgery with chemotherapy. According to the latest data, laparoscopic surgery is preferred, as it is less invasive and has a fas ter recovery than debulking operations. Tumor progression and tumor recurrence occurs more frequentl y in advanced stages. Conclusion. Currently, ovarian cancer remains one of the most com mon causes of lethality in women, the main cause being the lack of effective strat egies for early detection of ovarian cancer. The latest studies show that median survival for stage 1 ov arian cancer is between 70% and 90%, and for stage 4 it is less than 6%.
metadata.dc.relation.ispartof: MedEspera 2024
URI: https://ibn.idsi.md/collection_view/3104
http://repository.usmf.md/handle/20.500.12710/28634
ISBN: 978-9975-3544-2-4
Appears in Collections:MedEspera 2024

Files in This Item:
File Description SizeFormat 
MEsp24_218.pdf348.09 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback